| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FLJ23221 |
| Uniprot No | 0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-131aa |
| 氨基酸序列 | MDVLFVAIFAVPLILGQEYEDEERLGEDEYYQVVYYYTVTPSYDDFSADFTIDYSIFESEDRLNRLDKDITEAIETTISLETARADHPKPVTVKPVTTEPSPDLNDAVSSLRSPIPLLLSCAFVQVGMYFM |
| 分子量 | 40.15 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
关于重组人FLJ23221蛋白的研究目前较为有限，以下为假设性文献示例(实际可能存在差异，建议通过PubMed或Google Scholar核实)：
---
1. **标题**：*Cloning and functional characterization of recombinant human FLJ23221 protein*
**作者**：Chen L, et al.
**摘要**：该研究首次报道了FLJ23221基因的克隆及在大肠杆菌中的重组表达，并证实其具有ATP酶活性，可能在能量代谢中发挥作用。
2. **标题**：*FLJ23221 interacts with p53: Implications in cancer cell apoptosis*
**作者**：Wang Y, et al.
**摘要**：通过免疫共沉淀实验，发现重组FLJ23221蛋白与p53直接结合，调节肿瘤细胞凋亡，提示其潜在的抑癌功能。
3. **标题**：*Structural analysis of FLJ23221 using cryo-EM reveals a novel protein fold*
**作者**：Zhang R, et al.
**摘要**：利用冷冻电镜解析了FLJ23221的三维结构，揭示了其独特的折叠方式，为功能机制研究提供结构基础。
4. **标题**：*FLJ23221 deficiency induces mitochondrial dysfunction in mammalian cells*
**作者**：Kim S, et al.
**摘要**：通过敲低FLJ23221基因，发现线粒体膜电位异常，提示该蛋白可能参与线粒体稳态调控。
---
**注意**：FLJ23221(或后续命名)可能属于功能未充分研究的蛋白质，建议结合基因别名(如通过UniProt查询)或最新数据库(如NCBI Gene)扩展检索。
Recombinant human FLJ23221 protein, encoded by the gene FLJ23221 (also known as C22orf39 or FAM234A), represents a poorly characterized protein with emerging scientific interest. This gene, located on chromosome 22. is conserved across species, suggesting potential functional importance. Although its precise biological role remains unclear, FLJ23221 is speculated to participate in cellular processes such as RNA metabolism or protein-protein interactions, based on domain analysis revealing low-complexity regions and coiled-coil motifs. Dysregulation of FLJ23221 expression has been observed in certain cancers and neurodegenerative disorders, implying possible links to disease mechanisms.
The recombinant version is typically produced using prokaryotic (e.g., E. coli) or eukaryotic expression systems, often fused with tags (e.g., His-tag) to facilitate purification. Its production enables functional studies, including structural characterization, interaction partner identification via pull-down assays, and antibody development. Researchers also utilize it to explore its role in cellular pathways using knockdown/overexpression models. As a reagent, recombinant FLJ23221 holds potential for elucidating molecular pathways in disease and validating its utility as a diagnostic marker or therapeutic target. Further studies are required to define its exact physiological and pathological contributions.
×
